Discover Great Companies Discover Great Clients
Popularity  10.3万   |   Followers  46   |   Likes  32   |   Feedback  27 Claim this company

Dedicated to the research, development, production, and commercializat

No.3 Zhongshan Popularity Ranking No.3 Zhongshangang Street No.222 Guangdong No.1 Yao Products R&D No.1 Biopharmaceuticals No.1 Pharmaceutical Technology No.1 Lin Chuang Yi Xue No.1 Healthcare Technology No.1 Biological Products No.1 Sheng Wu Ke Ji / Biotechnology Engineering No.1 Pharmaceutical Industrial Innovative Drugs Shuang Te Yi Xing Kang Ti Antibodies Biotechnology Pharmaceuticals 省级高新技术企业 高新技术企业 省级专精特新中小企业 国家知识产权示范企业 省级创新型中小企业 国家知识产权优势企业
More

Company Overview

  • Nature: Listed Company Size: 1000-4999 employees Founded: 14年
  • Industry: Pharmaceutical/Bioengineering
  • Full name: Zhongshan Akeso Biomedical Pharmaceutical Co., Ltd.。

Development Stage

  • Stage: 战略投资, 35.2亿港元。
  • Ranking: Ranked #3 in Zhongshan by popularity Ranked #1 in Zhongshan Yao Products R&D Company by popularity Ranked #1 in Zhongshan Biopharmaceuticals Company by popularity Ranked #1 in Zhongshan Pharmaceutical Technology Company by popularity Ranked #1 in Zhongshan Lin Chuang Yi Xue Company by popularity
  • Honors: 2025中国新经济500强 省级高新技术企业 高新技术企业 According to algorithm
  • News: 2024-10-15:双抗龙头康方生物,融资超19亿港元。
  • Salary: 54.3% of positions earn 6-15K, In 2026 vs last yeardecreased by 4%.。Master's salary: ¥21.3K, Doctorate salary: ¥32.4K.
  • R&D: "Medical & Health/Beauty & Healthcare" demand: 35.4%, "Biology/Pharmaceutical/Chemical/Environmental Protection": 35.4%, "Computer/Network/Technology": 21%。
  • Recruiting: In 2026 vs 2025grew by 20%. Demand for highly educated talent: Master's: 53, Doctorate: 22.
  • Requirement: Education: 本科 leads with 57.2%. Experience: 不限 leads with 40.1%.
  • Region: Distributed across 28 regions, 中山: 42.6%, 广州: 22.4%, 北京: 5.3%, 上海: 4%.

About the Company

[Summary] Dedicated to the research, development, production, and commercializat

Akeso Biomedical (HKEX stock code: 9926.HK) is a biopharmaceutical company dedicated to the research, development, production, and commercialization of innovative antibody drugs affordable to patients worldwide.

Since its establishment, the company has built an integrated R&D innovation system centered on an end-to-end comprehensive drug development platform (ACE Platform) and bispecific antibody development technology (Tetrabody), a GMP production system meeting international standards, and an advanced commercialization system with sophisticated operational models.

The company currently possesses over 30 innovative drug candidates for the treatment of major diseases such as oncology, autoimmunity, inflammation, and metabolic disorders, among which 17 new drugs have entered clinical research, 14 pivotal/Phase III clinical trials are underway, and 3 new drugs have achieved commercial sales (including 1 out-licensed).

In August 2021, Anike (PD-1 monoclonal antibody, penpulimab injection) was approved for marketing.

In June 2022, the company's global bispecific immune checkpoint inhibitor, Kartini (PD-1/CTLA-4 bispecific antibody, cadonilimab injection), was approved for marketing.

In December 2022, another independently developed global bispecific antibody, Evoxi (PD-1/VEGF bispecific antibody, AK112), was granted development and commercialization rights to Summit Therapeutics in the United States, Canada, Europe, and Japan, under a collaboration agreement featuring an upfront payment of USD 500 million, a total transaction value of up to USD 5 billion, and a low double-digit percentage royalty on net sales.

Akeso Biomedical aspires to develop first-in-class and best-in-class therapeutic drugs through efficient and breakthrough R&D innovation, becoming a leading biopharmaceutical enterprise.

Expand
Information is aggregated from the web and may not be exact. For reference only.
Information incorrect? Claim this company to edit

Akeso Biomedical Financing History (9 rounds)

Manage
战略投资
Capital Market Favor
Latest Financing Round
  • Date: ?
  • Amount: 35.2亿港元
  • Investor: 投资方未透露

Akeso Biomedical How Fast Is Hiring Growing? (263 open positions)

Manage
?
Growth Rate
2026 vs 2025
  • 2025: Up 32%
  • 2024: Up 132%
  • 2023: Down 32%
  • 2022: Up 1%
Akeso Biomedical Year-by-Year Hiring:
* Hiring was generally low during 2020-2022 due to the pandemic
Akeso Biomedical Campus Recruitment & Advanced Degree Talent Demand
Graduates 8 Interns 7 Master's 53 Doctorate 22
No.9
Company Recruitment Ranking in Zhongshan 򀀩
No.810
Recruitment Growth Ranking in Zhongshan 򀀩
No.10
Graduate Talent Ranking in Zhongshan 򀀩
No.3
Intern Talent Ranking in Zhongshan 򀀩
Note: How fast is hiring at Zhongshan Akeso Biomedical Pharmaceutical Co., Ltd. growing? Akeso Biomedical2026: 936 openings (up 20%), 2025: 777 openings (up 32%), 2024: 589 openings (up 132%), 2023: 254 openings (down 32%), 2022: 376 openings (up 1%), 2021: 371 openings. A rising curve may indicate expansion; a falling curve may indicate slower growth or good retention. Based on publicly available data, for reference only.

Akeso Biomedical Master's Degree Job Demand Analysis

(More)
?
Growth Rate
2026 vs 2025
  • 2025: Up 62%
  • 2024: Up 32%
  • 2023: Down 58%
  • 2022: Up 3%
Akeso Biomedical Master's Hiring by Year:
* Hiring was generally low during 2020-2022 due to the pandemic
How fast is master's hiring at Zhongshan Akeso Biomedical Pharmaceutical Co., Ltd. growing? Akeso BiomedicalMaster's recruitment over the years: 2025: 60 openings (up 62%), 2024: 37 openings (up 32%), 2023: 28 openings (down 58%), 2022: 66 openings (up 3%), 2021: 64 openings. Akeso Biomedical master talent ranking in Zhongshan: #2, Akeso Biomedical master salary mostly around 10-30K.

Akeso Biomedical Doctoral Degree Job Demand Analysis

(More)
+70%
Growth Rate
2026 vs 2025
  • 2025: Up 54%
  • 2024: Up 271%
  • 2023: Down 46%
  • 2022: Up 63%
Akeso Biomedical Doctoral Hiring by Year: 2026 — 28 more jobs than 2025
* Hiring was generally low during 2020-2022 due to the pandemic
How fast is doctoral hiring at Zhongshan Akeso Biomedical Pharmaceutical Co., Ltd. growing? Akeso BiomedicalDoctorate recruitment over the years: 2026: 68 openings (up 70%), 2025: 40 openings (up 54%), 2024: 26 openings (up 271%), 2023: 7 openings (down 46%), 2022: 13 openings (up 63%), 2021: 8 openings. Akeso Biomedical doctorate talent ranking in Zhongshan: #1, Akeso Biomedical doctorate salary mostly around 20-50K.

Akeso Biomedical R&D Strength (Technical Talent Demand)

(More)
How is the demand for technical talent at Zhongshan Akeso Biomedical Pharmaceutical Co., Ltd.? Based on an analysis of Akeso Biomedical's job postings over the past year, "Medical & Health/Beauty & Healthcare" demand: 35.4%, "Biology/Pharmaceutical/Chemical/Environmental Protection": 35.4%, "Computer/Network/Technology": 21%, "Scientific Research": 7.8%, "Other (R&D and Technical)": 5.1%, "Mechanical/Instrumentation": 2.4%. For reference only.

Akeso Biomedical — What Are the Salaries Like? (1108 records)

Manage
salary range: 4.5K - 50K, 54.3% of roles pay ¥6-15K
Note: salary statistics are based on 1108 salary records from the past year and depend on the job sample. For reference only.
How is the salary at Zhongshan Akeso Biomedical Pharmaceutical Co., Ltd.?Akeso Biomedical54.3% of positions earn 6-15K, Fresh graduate salary: ¥9.0K。Zhongshan salary ranking top 5,生物/制药/化工/环保类 average salary ¥17.6K。 Note: Based on analysis of job postings, does not represent current on-the-job positions; system stability may affect objectivity. For reference only.Data inaccurate? Let us know

Salaries for hot jobs of Akeso Biomedical

(More)
Are salaries high at Zhongshan Akeso Biomedical Pharmaceutical Co., Ltd.? We provide: Information, RA, 科学家, Process Assistant, Analyst, 临床, Research Assistant, Pharmaceutical Sales Representative, QC, Medical Science Liaison, Regional Manager, Medical Manager, Senior Specialist, BP, Vice President, Finance Specialist, Medical Science Liaison, Quality, Production Technician, HR. Click to view detailed salary analysis by job.

Akeso Biomedical — Fortune 500? (More)

Yes, ranked in 中国新经济500强:

  • NO.151 2025中国新经济500强 >
  • NO.205 2024中国新经济500强 >
  • NO.335 2023中国新经济500强 >

Akeso Biomedical honors, qualifications & industry associations

Tags are labelled based on keyword text matching analysis and may be related to the company. For reference only.

Job Category

  • 生物/制药/化工/环保类
    35% of total 35%
  • 医疗卫生/美容保健类
    34.7% of total 34.7%
  • 销售类
    27.5% of total 27.5%
  • 计算机/网络/技术类
    20.4% of total 20.4%

Education

  • 本科
    57.2% of total 57.2%
  • 硕士
    16.2% of total 16.2%
  • 大专
    11.7% of total 11.7%
  • 博士
    7.4% of total 7.4%

Experience

  • 不限
    40.1% of total 40.1%
  • 1-3年
    28.8% of total 28.8%
  • 3-5年
    17.8% of total 17.8%
  • 5-10年
    10% of total 10%
View Detailed Analysis

What does Zhongshan Akeso Biomedical Pharmaceutical Co., Ltd. require? Who is Akeso Biomedical hiring? Akeso Biomedical recruitment: 生物/制药/化工/环保类占比最多占35%,其次是医疗卫生/美容保健类占34.7%. What education can get in at Akeso Biomedical? 本科占比最多占57.2%,其次是硕士占16.2%. High education required at Akeso Biomedical? 硕士占16.2%,博士占7.4%. Work experience required at Akeso Biomedical? 不限占比最多占40.1%,其次是1-3年占28.8%. Where are the job locations at Akeso Biomedical? 中山占比最多占42.6%,其次是广州占22.4%. Based on job postings from the past year, for reference only.

Business Registration

Provided by

Operating Status: 开业
Registered Capital: 535,000万(元)
Legal Representative: XIA YU
Date Established:
Credit Code: 91442000590136839L
Registered Address: 中山市火炬开发区神农路6号

Partners & Suppliers

国药股份参与分销康方生物的卡度尼利单抗 Source
合作客户 生物制品(单抗/重组蛋白)
AI辅助抗体药物设计 Source
供应商 制药行业合作
药明生物为康方生物提供抗体药物的发现、开发及生产(CDMO)服务。 Source
供应商 CDMO/CMO
泰格医药为康方生物提供临床试验设计、监查、数据管理等CRO服务。 Source
供应商 临床CRO
康方生物将AK112在美国、加拿大等地的开发及商业化权利授权给辉瑞,辉瑞支付首付款和里程碑付款。 Source
合作客户 药品授权许可

People who follow Akeso Biomedical also follow

Akeso Biomedical Competitors (Similar Companies)

“Professional manufacturer of sports shoes”
制药/药业 化妆品 护肤 唇膏
“A biopharmaceutical company dedicated to the research, development, pr”
电子厂/电子 光电 光电子 基板
“Research, development, and production of anti-tumor and surgical medic”
“To develop high-quality biologics that are accessible and affordable f”
“One of the world's top 10 wind turbine manufacturers, providing full l”
“Innovation for Life”
“is a modern, international, Sino-foreign joint venture pharmaceutical ”
空调 中央空调 商用空调 空气能
“New energy vehicle manufacturer”
“Rapid test product R&D and manufacturer”
“Dedicated to the research and development of molecularly targeted drug”
“让生命更有价值”
“A pharmaceutical company specializing in new drug R&D, production, and”

Discover Great Companies, Discover Great Clients

中山公司名录 中山“Zhongshangang Subdistrict”公司名录 中山“药物研发”公司名录 中山“生物医药”公司名录 中山“生物科技/生物工程”公司名录 中山“生物制品”公司名录 中山“医疗科技”公司名录 附近的公司

Report

*Reason:

Radical political or ideological topics
Advertising or spam
Pornographic or vulgar content
Obscene language or personal attacks
Other

Congratulations, submitted successfully!

Your edit is under review. You will be notified by email within 1 business day.

Submission failed.

Followed successfully. We'll notify you of any company updates.

Help others learn about this company, add my impression of this company»

Log in with the following accounts to save your follows

Followed successfully, we'll notify you of any company updates